Safety and Efficacy of Citrate Anticoagulation in Liver Failure Patients
Author Information
Author(s): Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, Andersen K, Wehner M, Kozik-Jaromin J, Brett S, Hasslacher J, Stover JF, Peters H, Neumayer HH, Kindgen-Milles D
Primary Institution: Charité CCM, Berlin, Germany
Hypothesis
Can regional citrate anticoagulation be safely used in ICU patients with liver dysfunction?
Conclusion
Citrate-CVVHD can be safely used in patients with liver dysfunction, providing excellent filter patency and avoiding bleeding.
Supporting Evidence
- 56% of ICU admissions were medical cases.
- 39% of liver failures were due to ischemia.
- 96% of filters were running after 72 hours when excluding non-clotting causes.
Takeaway
This study shows that using citrate for blood thinning in patients with liver problems is safe and works well.
Methodology
Prospective observation of 133 adult ICU patients for 72 hours of citrate-CVVHD, stratified by serum bilirubin levels.
Participant Demographics
Adult ICU patients with varying levels of liver function.
Statistical Information
P-Value
P = 0.41 for severe alkalosis, P = 0.95 for severe acidosis, P = 0.57 for severe hypocalcemia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website